FloBio / About FloBio
Reimagining Hemostasis Testing By Filling The Information Gap To Impact Clinical Decision Making
FloBio LLC, formed in August 2017 as a spin-out of the University of Pennsylvania (UOP), is pioneering a novel fluidic-based diagnostic platform technology that assesses bleeding and thrombotic risk at the point-of-care, with clinical applications being developed for emergency critical care patients. Although widely used in research labs, microfluidic devices have rarely been used at the point-of-care due to obstacles in manufacturing scale-up, and the technical expertise required. The company was founded by Dr. Scott Diamond, an expert in microfluidics and blood biology.
FloBio resides at the state-of-the-art Pennovation Center in Philadelphia, Pennsylvania and is portfolio company of Penn Center for Innovation Ventures (PCIV).
The company continues to advance its diagnostic technology, benchmarking progress to date with a Research Use Only (RUO) system successfully demonstrating technical and clinical feasibility.
World Class Team, Diverse, Proven Track Record
FloBio has compiled a world class team, including diagnostic industry leaders, clinical collaborators, and experts in emergency, trauma and critical care. Together, we are committed to bringing the long needed innovation to the hemostasis testing market.
Jerri Ann Thatcher
Scott L. Diamond
Founder, Scientific Advisor
Jason M. Rossi, PhD
Lead Research Scientist
IVD, Clinical, Regulatory Consultant
Bhavana Mohanraj, PhD
Business Advisor, PCIV
Dr. Alan Wright
Nicole Sunderland, RN
Dr. Adam Cuker
Dr. Niels Martin
Dr. Thomas Diacovo
Addressing The Need For Improved Hemostasis Testing
Empowering Rapid and Evidence Based Decision Making and Improving Outcomes
Existing testing approaches fail to provide an adequate understanding of blood clotting behavior, especially in the presence of anticoagulation drugs, taking too long for use in emergency care, or failing to identify the source of the problem. Clinicians are left with indirect or incomplete results and often leading to empiric treatment and/or delayed decisions or care.
Our first test in development addresses the growing need for Direct Oral Anticoagulant testing and evidence based reversl strategies by identifying DOAC presence, class and levels.
Proven Science and Versatile Platform
Our technology is based on more than 10 years of research from the Diamond Lab at the University of Pennsylvania’s Institute of Medicine and Engineering. Dr. Scott Diamond, FloBio’s founder, has produced more than 30 related publications, which demonstrate the scientific rationale and proof of concept; including a broad range of clinical and pharmacologic applications where understanding bleeding and clotting risk is essential.
Our versatile R&D pipeline includes tests for anticoagulation drug activity, trauma-induced coagulopathy, and neonate applications.
May 2022: NIH Phase 2 SBIR
August 2020: NIH Phase 1 SBIR
September 2019: NIH Phase 1 SBIR
November 2020: NSF Phase 1 SBIR
Spring 2021: NSF Bootcamp
March 2019: PPDC Grant Award